Iluvien

Fluocinolone Acetonide, the active ingredient in Iluvien, is a corticosteroid presented as a 0.19 mg intravitreal sustained‑release implant for intravitreal use. It treats diabetic macular edema and chronic non‑infectious posterior uveitis in adult patients.

GNH USA supplies Iluvien as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Iluvien is indicated for ocular conditions characterized by inflammation and fluid accumulation.

Diabetic macular edema: reduces retinal thickness and improves visual acuity. Chronic non‑infectious posterior uveitis: controls intra‑ocular inflammation and helps preserve vision.

Iluvien may cause ocular and systemic adverse reactions, which vary in frequency and severity.

Common Side Effects: - Elevated intraocular pressure - Cataract formation or progression - Vitreous floaters - Mild ocular discomfort or irritation - Conjunctival hyperemia - Transient blurred vision

Serious or Rare Side Effects: - Persistent or uncontrolled intraocular pressure leading to glaucoma - Endophthalmitis or intraocular infection - Retinal detachment or tear - Severe cataract requiring surgery - Vitreous hemorrhage

Prior to Iluvien implantation, clinicians should assess ocular health and consider patient history.

Monitor intraocular pressure: schedule regular pressure checks post‑implant. Assess cataract status: evaluate lens opacity before and after treatment. Avoid in active ocular infection: postpone implantation until infection resolves. Use with caution in patients with glaucoma or a history of steroid‑responsive pressure rise. Do not combine with other intraocular corticosteroid implants. Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Iluvien may interact with other ocular or systemic agents that affect intraocular pressure or inflammation.

Major Interactions (Avoid): - Concurrent use of other intravitreal corticosteroid implants: risk of additive pressure elevation. - Systemic potent CYP3A4 inducers (e.g., rifampin) that could alter steroid metabolism.

Moderate Interactions (Monitor Closely): - Topical ocular steroids: monitor intraocular pressure closely. - Antiglaucoma medications: adjust dosing if intraocular pressure rises. - Anticoagulants: watch for increased risk of intraocular hemorrhage during implantation.